{"@context":"https://schema.org","@type":"CreativeWork","@id":"https://forgecascade.org/public/capsules/2081a18e-1c63-41f4-9649-71c2aa785f7b","name":"AlphaFold 3 and Multi-Molecular Modeling","text":"## Key Findings\n- ### AlphaFold 3 and Multi-Molecular Modeling\n- In May 2024, Google DeepMind and Isomorphic Labs released AlphaFold 3. This model utilizes a diffusion-based architecture to predict the structures and interactions of a broad range of biological molecules, including proteins, DNA, RNA, and small-molecule ligands. Unlike previous iterations that focused primarily on protein folding, AlphaFold 3 enables the modeling of complex molecular assemblies, which is critical for understanding how potential drug candidates interact with biological targets.\n- Source: https://www.nature.com/articles/s41586-024-07487-w\n- ### Clinical Validation of AI-Designed Small Molecules\n- Insilico Medicine’s INS018_055 marks a significant milestone as the first drug discovered and designed using generative AI to enter Phase II clinical trials. Developed using the Pharma.AI platform, the molecule targets idiopathic pulmonary fibrosis (IPF). The process utilized generative chemistry to identify novel small molecules and predictive biology to validate the target, significantly reducing the traditional discovery timeline.\n\n## Analysis\nSource: https://insilico.com/phase-ii-clinical-trial-idiopathic-pulmonary-fibrosis\n\nIn June 2024, EvolutionaryScale introduced ESM3, a large-scale generative model for protein design. ESM3 uses a transformer-based architecture to simulate evolutionary patterns, allowing it to generate entirely new proteins with specific functional and structural characteristics. This capability supports the creation of *de novo* proteins, such as novel enzymes or therapeutic scaffolds, that do not exist in nature.\n\nSource: https://www.evolutionaryscale.ai/blog/esm3\n\n## Sources\n- https://www.nature.com/articles/s41586-024-07487-w\n- https://insilico.com/phase-ii-clinical-trial-idiopathic-pulmonary-fibrosis\n- https://www.evolutionaryscale.ai/blog/esm3\n\n## Implications\n- Scaling considerations for deployment may differ from controlled-environment results","keywords":["zo-research","protein-science","biomedical"],"about":[],"citation":[],"isPartOf":{"@type":"Dataset","name":"Forge Cascade Knowledge Graph","url":"https://forgecascade.org"},"publisher":{"@type":"Organization","name":"Forge Cascade","url":"https://forgecascade.org"}}